Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-12-26
2006-12-26
Nguyen, Quang (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S455000
Reexamination Certificate
active
07153951
ABSTRACT:
Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.
REFERENCES:
patent: 4698328 (1987-10-01), Neer et al.
patent: 4761406 (1988-08-01), Flora et al.
patent: 5217896 (1993-06-01), Kramer et al.
patent: 5382658 (1995-01-01), Kronis et al.
patent: 5556940 (1996-09-01), Willick et al.
patent: 5717062 (1998-02-01), Chorev et al.
patent: 6066618 (2000-05-01), Holick
patent: 2126132 (1995-12-01), None
patent: 0 783 522 (2001-12-01), None
patent: WO 91/05050 (1991-04-01), None
patent: WO 96/19206 (1996-06-01), None
patent: WO 98/05683 (1998-02-01), None
Dang et al. Gene therapy and translational cancer research. Clin. Cancer Res. 5:471-474, 1999.
Romano et al. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18:19-39, 2000.
Hammer et al. Genetic engineering of mammalian embryos. J. Animal Sci. 63:269-278, 1986.
Ebert et al. A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig. Molecular Endocrinology 2:277-283, 1988.
Strojek et al. The use of transgenic animal techniques for livestock improvement. In Genetic Engineering: Principles and methods, vol. 10, pp. 221-246, 1988.
Kappel et al. Regulating gene expression in transgenic animals. Current Opinion in Biotechnology 3:548-553, 1992.
Mullins et al. Perspective series: Molecular medicine in genetically engineered animals. J. Clin. Invest. 98:S37-S40, 1996.
Wall, R.J. Transgenic livestock: Progress and prospects for the future. Theriogenology 45:57-68, 1996.
Alberts et al. In: Molecular Biology of The Cell, 3rd Edition, Garland Publishing, New York, 1994, pp. 234-237 and the Genetic Code Table.
Abou-Samra, A.-B., et al., “Non-Homologous Sequences of Parathyroid Hormone and the Parathyroid Hormone Related Peptide Bind to a Common Receptor on ROS 17/2.8 Cells,”Endocrinology 125:2215-2217, The Endocrine Society (1989).
Azarani, A., et al., “Structurally Diverse N-terminal Peptides of Parathyroid Hormone (PTH) and PTH-related Peptide (PTHRP) Inhibit the NA+/H+Exchanger NHE3 Isoform by Binding to the PTH/PTHRP Receptor Type I and Activating Distinct Signaling Pathways,”J. Biol. Chem. 271:14931-14936, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Bergwitz, C., et al., “Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin,”J. Biol. Chem. 271:26469-26472, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Born, W., et al., “Inhibition of Parathyroid Hormone Bioactivity by Human Parathyroid Hormone (PTH)—(3-84) and PTH- (8-84) Synthesized inEscherichia coli,” Endocrinology 123:1848-1853, The Endocrine Society (1988).
Caulfield, M.P. et al., “The Bovine Renal Parathyroid Hormone (PTH) Receptor Has Equal Affinity for Two Different Amino Acid Sequences: The Receptor Binding Domains of PTH and PTH-Related Protein Are Located within the 14-34 Region,”Endocrinology 127:83-87, The Endocrine Society (1990).
Dempster, D.W., et al., “Anabolic Actions of Parathyroid Hormone on Bone,”Endocr. Rev. 14:690-709, The Endocrine Society (1993).
Dempster, D.W., et al., “Anabolic Actions of Parathyroid Hormone on Bone,”Endocr. Rev. 14:690-709 (1993), published erratum appears inEndocr. Rev. 15:261, The Endocrine Society (1994).
Ding, Y., et al., “A Single Amino Acid Determines the Immunostimulatory Activity of Interleukin 10,”J. Exp. Med. 191:213-223, The Rockefeller University Press (Jan. 2000).
Fairwell, T., et al., “Total Solid-Phase Synthesis, Purification, and Characterization of Human Parathyroid Hormone- (1-84),”Biochemistry 22:2691-2697, American Chemical Society (1983).
Gardella, T.J., et al., “Analysis of Parathyroid Hormone's Principal Receptor-Binding Region by Site-Directed Mutagenesis and Analog Design,”Endocrinology 132:2024-2030, The Endocrine Society (1993).
Gardella, T.J., et al., “Mutational Analysis of the Receptor-activating Region of Human Parathyroid Hormone,”J. Biol. Chem. 266:13141-13146, The American Society for Biochemistry and Molecular Biology, Inc. (1991).
Goltzmann, D., et al., “Analysis of the Requirements for Parathyroid Hormone Action in Renal Membranes with the Use of Inhibiting Analogues,”J. Biol. Chem. 250:3199-3203, The American Society for Biochemistry and Molecular Biology, Inc. (1975).
Goud, N.A., et al., “Solid-Phase Synthesis and Biologic Activity of Human Parathyroid Hormone (1-84),”J. Bone Miner. Res. 6:781-789, Mary Ann Liebert, Inc. (1991).
Horiuchi, N., et al., “A Parathyroid Hormone Inhibitor in vivo: Design and Biological Evaluation of a Hormone Analog,”Science 220:1053-1055, American Association for the Advancement of Science (1983).
Jūppner, H., et al., “The Parathyroid Hormone-like Peptide Associated with Humoral Hypercalcemia of Malignancy and Parathyroid Hormone Bind to the Same Receptor on the Plasma Membrane of ROS 17/2.8 cells,”J. Biol. Chem. 263:8557-8560. The American Society for Biochemistry and Molecular Biology, Inc. (1988).
Kemp, B.E., et al., “Parathyroid Hormone-Related Protein of Malignancy: Active Synthetic Fragments,”Science 238:1568-1570, American Association for the Advancement of Science (1987).
Kimura, T., et al., “Strategy for the Synthesis of Large Peptides: An Application to the Total Synthesis of Human Parathyroid Hormone [hPTH (1-84) ],”Biopolymers 20:1823-1832, John Wiley & Sons, Inc. (1981).
Musso, M.-J., et al., “Renal vasodilatation and microvessel adenylate cyclase stimulation by synthetic parathyroid hormone-like protein fragments,”Eur. J. Pharmacol. 174:139-151, Elsevier (1989).
Nussbaum, S.R., et al., “Parathyroid Hormone•Renal Receptor Interactions,”J. Biol. Chem. 255:10183-10187, The American Society of Biological Chemists, Inc. (1980).
Orkin, S.H., et al., Report and recommendations of the panel to assess the NIH investment in research on gene therapy, NIH, pp. 1-39 (Dec. 1995) retrieved on Aug. 5, 2002 from www.nih.gov
ews/panelrep.html.
Rixon, R.H., et al., “Parathyroid Hormone Fragments May Stimulate Bone Growth in Ovariectomized Rats by Activating Adenlyl Cyclase,”J. Bone Miner. Res. 9:1179-1189, Mary Ann Liebert, Inc. (1994).
Rosenblatt, M., “Parathyroid Hormone: Chemistry and Structure-Activity Relations,”Pathobiol. Annu. 11:53-86, Raven Press (1981).
Shen, V., et al., “Effects of Combined and Separate Intermittent Administration of Low-Dose Human Parathyroid Hormone Fragment (1-34) and 17β-Estradiol on Bone Histomorphometry in Ovariectomized Rats with Established Osteopenia,”Calcif. Tissue Int. 50:214-220, Springer-Verlag (1992).
Slovik, D.M., et al., “Restoration of Spinal Bone in Osteoporotic Men by Treatment With Human Parathyroid Hormone (1-34) and 1,25-Dihydroxyvitamin D,”J. Bone Miner. Res. 1:377-381, Mary Ann Liebert, Inc. (1986).
Takasu, H., et al., “Human PTH/PTHrP Receptors and Type-2 PTH Receptors Show Discordant Selectivity for Human PTH Analogs with Amino-Terminal Modifications,”Bone 23:s255, Abstract No. T223, Elsevier (Nov. 1998).
Takasu, H., et al., “Phospholipase C Activation via the Human PTH/PTHrP Receptor Requires an Intac
Gardella Thomas J
Jüppner Harald
Kronenberg Henry M
Potts, Jr. John T
Nguyen Quang
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
LandOfFree
Bioactive peptides and peptide derivatives of parathyroid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bioactive peptides and peptide derivatives of parathyroid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioactive peptides and peptide derivatives of parathyroid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655502